Learn More
In this paper, we propose a novel continuum robot based on closed loop elastic structure with bending and twisting. The proposed continuum robot consists of an elastic tube and a closed loop arm completely independent from the tube. The closed loop arm is a simple thin belt-shaped elastic strip which has two translational joints and one rotary degree of(More)
We measured the energy expenditure weekly in patients undergoing a pylorus preserving pancreatoduodenectomy for bile duct cancer or pancreatic tumors. Twelve patients (5 women and 7 men; mean age 70.1 years) were enrolled in this study, and their resting energy expenditure levels were determined by indirect calorimetry. In these patients, a significant(More)
PURPOSE We retrospectively evaluated the in vitro chemosensitivity of primary site and metastatic site tumors in colorectal cancer. METHODS Various resected tumor samples (33 from lymph nodes, 42 from liver, six from lung, and 68 primary tumors) were assessed via a collagen gel droplet-embedded culture drug sensitivity test to determine chemosensitivity(More)
BACKGROUND Lymphoepithelial cyst (LEC) of the pancreas is a rare benign tumor. LEC with sebaceous glands of the pancreas is extremely rare, and its histogenesis remains unclear. CASE PRESENTATION We present a 66-year-old man with an incidental finding of a cystic lesion at the neck of the pancreas. Pancreatic juice cytology results and elevated serum(More)
Hepatocellular carcinoma (HCC) is one of the most intractable and lethal cancers; most cases are diagnosed at advanced stages with underlying liver dysfunction and are frequently resistant to conventional chemotherapy and radiotherapy. The development of tumor-targeting systems may improve treatment outcomes. Nanomedicine platforms are of particular(More)
BACKGROUND Pancreatic ductal adenocarcinoma, which represents 90% of pancreatic cancers, is one of the most lethal and aggressive malignancies. Operative resection remains the only treatment providing prolonged survival, however, recurrence of pancreatic ductal adenocarcinoma occurs in up to 80% of patients with pancreatic cancer within 2 years of a(More)
In July 2008, cetuximab, a monoclonal anti-body against epidermal growth factor receptor (EGFR), was approved in Japan for clinical use against chemo-therapy-refractory metastatic colorectal cancer (mCRC). At a total of 24 EGFR-positive mCRC cases were administered immunohistochemistry with cetuximab as salvage monotherapy. The safety, side-effects and(More)
  • 1